Medtech Zynex's Q2 revenue falls more than expected, names new CEO, suspends forecast

Zynex

31/07/2025 21:16

Overview

Zynex Q2 2025 revenue falls 55% yr/yr, missing analyst expectations, per LSEG data

Net loss widens to $20 mln, or $0.66 per share, in Q2 2025

Co appoints Steven Dyson as new CEO, aims for strategic refocus

Outlook

Company suspends revenue and profitability guidance due to leadership changes

New CEO to review forecasting procedures and update investors

Company expects $40 mln annualized savings to take effect in Q3 and Q4

Result Drivers

REVENUE DECLINE - Revenue impacted by Tricare payment suspension and changes to shipment and billing procedures

FDA SUBMISSION - NiCO laser pulse oximeter submitted to FDA, marking a milestone in product development

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$22.30 mln
$27.40 mln (3 Analysts)
Q2 EPS
-$0.66
Q2 Net Income
-$20 mln
Q2 Adjusted EBITDA
-$8.90 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Zynex Inc is $6.00, about 58.5% above its July 30 closing price of $2.49

Press Release: ID:nPn5CVS51a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)